331 related articles for article (PubMed ID: 22090419)
61. Curcumin analogue UBS109 prevents bone loss in breast cancer bone metastasis mouse model: involvement in osteoblastogenesis and osteoclastogenesis.
Yamaguchi M; Zhu S; Zhang S; Wu D; Moore TM; Snyder JP; Shoji M
Cell Tissue Res; 2014 Jul; 357(1):245-52. PubMed ID: 24723227
[TBL] [Abstract][Full Text] [Related]
62. Taxifolin Inhibits Receptor Activator of NF-κB Ligand-Induced Osteoclastogenesis of Human Bone Marrow-Derived Macrophages in vitro and Prevents Lipopolysaccharide-Induced Bone Loss in vivo.
Zhang HQ; Wang YJ; Yang GT; Gao QL; Tang MX
Pharmacology; 2019; 103(1-2):101-109. PubMed ID: 30522105
[TBL] [Abstract][Full Text] [Related]
63. Cafestol has a weaker inhibitory effect on osteoclastogenesis than kahweol and promotes osteoblast differentiation.
Fukuma Y; Sakai E; Nishishita K; Okamoto K; Tsukuba T
Biofactors; 2015; 41(4):222-31. PubMed ID: 26154488
[TBL] [Abstract][Full Text] [Related]
64. Sargachromanol G inhibits osteoclastogenesis by suppressing the activation NF-κB and MAPKs in RANKL-induced RAW 264.7 cells.
Yoon WJ; Kim KN; Heo SJ; Han SC; Kim J; Ko YJ; Kang HK; Yoo ES
Biochem Biophys Res Commun; 2013 May; 434(4):892-7. PubMed ID: 23611776
[TBL] [Abstract][Full Text] [Related]
65. Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation.
Yang C; Davis JL; Zeng R; Vora P; Su X; Collins LI; Vangveravong S; Mach RH; Piwnica-Worms D; Weilbaecher KN; Faccio R; Novack DV
Cancer Discov; 2013 Feb; 3(2):212-23. PubMed ID: 23269702
[TBL] [Abstract][Full Text] [Related]
66. Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer.
Takayama K; Inoue T; Narita S; Maita S; Huang M; Numakura K; Tsuruta H; Saito M; Maeno A; Satoh S; Tsuchiya N; Habuchi T
Cancer Lett; 2017 Jul; 397():103-110. PubMed ID: 28373003
[TBL] [Abstract][Full Text] [Related]
67. Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity.
Yip KH; Zheng MH; Feng HT; Steer JH; Joyce DA; Xu J
J Bone Miner Res; 2004 Nov; 19(11):1905-16. PubMed ID: 15476591
[TBL] [Abstract][Full Text] [Related]
68. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
[TBL] [Abstract][Full Text] [Related]
69. I‑BET151 inhibits osteoclastogenesis via the RANKL signaling pathway in RAW264.7 macrophages.
Cheng J; Zheng J; Guo N; Zi F
Mol Med Rep; 2017 Dec; 16(6):8406-8412. PubMed ID: 28983590
[TBL] [Abstract][Full Text] [Related]
70. Protein kinase C inhibitor, GF109203X attenuates osteoclastogenesis, bone resorption and RANKL-induced NF-κB and NFAT activity.
Yao J; Li J; Zhou L; Cheng J; Chim SM; Zhang G; Quinn JM; Tickner J; Zhao J; Xu J
J Cell Physiol; 2015 Jun; 230(6):1235-42. PubMed ID: 25363829
[TBL] [Abstract][Full Text] [Related]
71. Amyloid β Peptide Enhances RANKL-Induced Osteoclast Activation through NF-κB, ERK, and Calcium Oscillation Signaling.
Li S; Yang B; Teguh D; Zhou L; Xu J; Rong L
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27735865
[TBL] [Abstract][Full Text] [Related]
72. Bergapten suppresses RANKL-induced osteoclastogenesis and ovariectomy-induced osteoporosis via suppression of NF-κB and JNK signaling pathways.
Chen G; Xu Q; Dai M; Liu X
Biochem Biophys Res Commun; 2019 Feb; 509(2):329-334. PubMed ID: 30579598
[TBL] [Abstract][Full Text] [Related]
73. Asiaticoside, a component of Centella asiatica attenuates RANKL-induced osteoclastogenesis via NFATc1 and NF-κB signaling pathways.
He L; Hong G; Zhou L; Zhang J; Fang J; He W; Tickner J; Han X; Zhao L; Xu J
J Cell Physiol; 2019 Apr; 234(4):4267-4276. PubMed ID: 30146787
[TBL] [Abstract][Full Text] [Related]
74. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.
Yang JC; Bai L; Yap S; Gao AC; Kung HJ; Evans CP
Mol Cancer Ther; 2010 Jun; 9(6):1629-37. PubMed ID: 20484016
[TBL] [Abstract][Full Text] [Related]
75. Sanguiin H-6, a constituent of Rubus parvifolius L., inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis and bone resorption in vitro and prevents tumor necrosis factor-α-induced osteoclast formation in vivo.
Sakai E; Aoki Y; Yoshimatsu M; Nishishita K; Iwatake M; Fukuma Y; Okamoto K; Tanaka T; Tsukuba T
Phytomedicine; 2016 Jul; 23(8):828-37. PubMed ID: 27288918
[TBL] [Abstract][Full Text] [Related]
76. Rhinacanthin C Inhibits Osteoclast Differentiation and Bone Resorption: Roles of TRAF6/TAK1/MAPKs/NF-κB/NFATc1 Signaling.
Tomomura M; Suzuki R; Shirataki Y; Sakagami H; Tamura N; Tomomura A
PLoS One; 2015; 10(6):e0130174. PubMed ID: 26083531
[TBL] [Abstract][Full Text] [Related]
77. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
78. Sophocarpine attenuates wear particle-induced implant loosening by inhibiting osteoclastogenesis and bone resorption via suppression of the NF-κB signalling pathway in a rat model.
Zhou CH; Shi ZL; Meng JH; Hu B; Zhao CC; Yang YT; Yu W; Chen ZX; Heng BC; Parkman VA; Jiang S; Zhu HX; Wu HB; Shen WL; Yan SG
Br J Pharmacol; 2018 Mar; 175(6):859-876. PubMed ID: 29130485
[TBL] [Abstract][Full Text] [Related]
79. Sagopilone inhibits breast cancer bone metastasis and bone destruction due to simultaneous inhibition of both tumor growth and bone resorption.
Strube A; Hoffmann J; Stepina E; Hauff P; Klar U; Käkönen SM
Clin Cancer Res; 2009 Jun; 15(11):3751-9. PubMed ID: 19470728
[TBL] [Abstract][Full Text] [Related]
80. Pharmacological evidence for the bone-autonomous contribution of the NFκB/β-catenin axis to breast cancer related osteolysis.
Marino S; Bishop RT; Logan JG; Mollat P; Idris AI
Cancer Lett; 2017 Dec; 410():180-190. PubMed ID: 28965856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
